Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up to $7.70

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) gapped up prior to trading on Wednesday . The stock had previously closed at $7.70, but opened at $8.15. Recursion Pharmaceuticals shares last traded at $8.17, with a volume of 2,353,803 shares.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RXRX. KeyCorp increased their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Trading Down 1.3 %

The firm has a fifty day simple moving average of $10.47 and a 200 day simple moving average of $9.11.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. The company had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10. Following the sale, the director now owns 7,312,917 shares of the company’s stock, valued at approximately $68,010,128.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10. Following the sale, the director now owns 7,312,917 shares of the company’s stock, valued at approximately $68,010,128.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Gibson sold 48,272 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total value of $445,067.84. Following the sale, the chief executive officer now directly owns 774,703 shares in the company, valued at approximately $7,142,761.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 348,218 shares of company stock valued at $3,536,464. 19.96% of the stock is currently owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. National Bank of Canada FI boosted its position in shares of Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after purchasing an additional 1,500 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock worth $40,000 after purchasing an additional 2,817 shares in the last quarter. First Horizon Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth $47,000. Allspring Global Investments Holdings LLC lifted its position in Recursion Pharmaceuticals by 25.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after acquiring an additional 2,050 shares during the period. Finally, Private Advisor Group LLC acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter worth about $79,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.